FTC says divestiture will remove antitrust issue on Eli Lilly-Novartis deal
MLex Summary: The proposed divestiture of Eli Lilly's Sentinel product line and associated assets to the French pharmaceutical company Virbac will remedy antitrust problems with the proposed merger between Eli Lilly and Novartis,...To view the full article, register now.
Already a subscriber? Click here to view full article